Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

Core Insights - The Phase 1 INTERCEPT-AD trial results support the continued development of sabirnetug (ACU193) for early Alzheimer's disease treatment, showing selective target engagement and significant amyloid plaque reduction [1][3][4] - Acumen Pharmaceuticals is advancing sabirnetug as a next-generation antibody treatment, targeting toxic soluble amyloid beta oligomers (AβOs) that contribute to Alzheimer's disease pathology [2][8] - The ongoing Phase 2 ALTITUDE-AD trial aims to evaluate the efficacy and safety of sabirnetug in approximately 540 adults with early Alzheimer's disease, with enrollment expected to complete in the first half of 2025 [6][10] Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies targeting toxic soluble AβOs for Alzheimer's disease [11] - The company has received Fast Track designation from the U.S. FDA for sabirnetug, indicating its potential as a treatment for early Alzheimer's disease [8] - The INTERCEPT-AD trial involved 65 participants and demonstrated a favorable safety profile, with low levels of amyloid-related imaging abnormalities [3][9] Clinical Trials - The INTERCEPT-AD trial was a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of sabirnetug in early Alzheimer's disease patients [3][9] - The ALTITUDE-AD trial is a multi-center, randomized, double-blind, placebo-controlled study evaluating sabirnetug's efficacy in slowing cognitive decline, with the first patient dosed in May 2024 [6][10]